OMER
NASDAQOmeros Corporation
Omeros Corporation (OMER) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for OMER, including 1 press release or news item, 1 SEC filing and 1 insider trade. The most recent was published Oct 30, 2026.
OMER rankings
Financial highlights
Full financials- Net income, TTM
- $124.83M
- Free cash flow, TTM
- -$68.73M
- Cash
- $1.99M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks42+50%
2026-05-102026-11-01
Mix2090d
- Insider9(45%)
- SEC Filings7(35%)
- Earnings2(10%)
- Analyst1(5%)
- Other1(5%)
Latest news
25 items- INSIDERChairman, CEO & President Demopulos Gregory A Md was granted 500,000 performance stock options (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- SECOmeros Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMAOmeros Corporation (NASDAQ:OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination process. The AHEG was charged with addressing a single
- INSIDERVP, Finance & CAO Borges David J. exercised 20,000 shares at a strike of $9.51 and sold $419,000 worth of shares (20,000 units at $20.95) as part of a pre-agreed trading plan (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- ANALYSTOmeros upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded Omeros from Neutral to Overweight and set a new price target of $22.00
- INSIDERVP, General Counsel Cancelmo Peter B exercised 50,000 shares at a strike of $2.94 and sold $929,668 worth of shares (50,000 units at $18.59) (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERDirector Hanish Arnold C sold $282,094 worth of shares (15,000 units at $18.81) and exercised 15,000 shares at a strike of $15.23 (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- SECSEC Form 144 filed by Omeros Corporation144 - OMEROS CORP (0001285819) (Subject)
- SECSEC Form 144 filed by Omeros Corporation144 - OMEROS CORP (0001285819) (Subject)
- INSIDERVP, Finance & CAO Borges David J. exercised 10,906 shares at a strike of $3.48 and sold $206,805 worth of shares (10,906 units at $18.96) as part of a pre-agreed trading plan (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERDirector Cable Thomas J. sold $276,772 worth of shares (15,000 units at $18.45) and exercised 15,000 shares at a strike of $2.96 (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Schocken Joseph L4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERNew insider Schocken Joseph L claimed ownership of 528,082 shares (SEC Form 3)3 - OMEROS CORP (0001285819) (Issuer)
- INSIDERVP, Finance & CAO Borges David J. exercised 5,000 shares at a strike of $3.93 and sold $84,750 worth of shares (5,000 units at $16.95) as part of a pre-agreed trading plan (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- SECSEC Form S-8 filed by Omeros CorporationS-8 - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Leadership Update8-K - OMEROS CORP (0001285819) (Filer)
- SECSEC Form 10-Q filed by Omeros Corporation10-Q - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Reports Second Quarter 2026 Financial Results– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an increase of 190% from $11.1 million in the first quarter. Net revenue was $28.5 million, reflecting gross-to-net adjustments of approximately 11.5%, compared with $9.9 million and 11.0%
- PROmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros’ website. A replay of the call will be available for 90 days in the "Archived Events" section of the Investor Relations page of O
- PRCMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®--Provides additional Medicare reimbursement to hospitals and supports patient access for eligible Medicare patients with TA-TMA-- Omeros Corporation (NASDAQ:OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) will receive additional Medicare reimbursement. YARTEMLEA is the first and only FDA-approved treatme
- INSIDERSEC Form 4 filed by Chairman, CEO & President Demopulos Gregory A Md4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by VP, General Counsel Cancelmo Peter B4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by VP, Finance & CAO Borges David J.4 - OMEROS CORP (0001285819) (Issuer)
- SECOmeros Corporation filed SEC Form 8-K: Other Events8-K - OMEROS CORP (0001285819) (Filer)
OMER FAQ
10 questionsWhat does Omeros Corporation do?
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for...What is the latest news on OMER?
In the last 30 days Quantisnow tracked 3 wire items for OMER: 1 press release or news item, 1 SEC filing and 1 insider trade. The most recent was published on October 30, 2026.Is OMER profitable?
Yes. Omeros Corporation earned $124.83M in net income for the twelve months ended Jun 30, 2026.How much cash and debt does OMER have?
Omeros Corporation reported $1.99M in cash and cash equivalents and $73.29M of debt on its most recent balance sheet in SEC filings.Where does OMER stock trade?
Omeros Corporation (OMER) is listed on NASDAQ.What sector and industry is OMER in?
Omeros Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Omeros Corporation go public?
Omeros Corporation (OMER) completed its IPO in 2009.What are analysts saying about OMER?
Across the last 8 analyst actions on Omeros Corporation, there was 1 upgrade and 3 downgrades. The most recent action was from Cantor Fitzgerald: Overweight with a $22.00 price target on 2026-09-22.What companies are similar to OMER?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OMER side-by-side with any of them on Quantisnow.How can I track OMER on Quantisnow?
Quantisnow aggregates Omeros Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OMER to receive live email and push alerts on every new disclosure.